213627-30-6

Basic information

• Product Name: 4-BROMOBENZYLMETHYLSULFONE
• Synonyms: 4-BROMOBENZYLMETHYLSULFONE;1-bromo-4-(methylsulfonylmethyl)benzene
• CAS NO: 213627-30-6
• Molecular Formula: C₈H₉BrO₂S
• Molecular Weight: 249.12
• Mol File: 213627-30-6.mol

Chemical Properties

• Melting Point: 134-136°C
• Boiling Point: 409.0±28.0 °C(Predicted)
• Appearance: /
• Density: 1.562±0.06 g/cm3(Predicted)
• CAS DataBase Reference: 4-BROMOBENZYLMETHYLSULFONE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BROMOBENZYLMETHYLSULFONE(213627-30-6)
• EPA Substance Registry System: 4-BROMOBENZYLMETHYLSULFONE(213627-30-6)

Safety Data

• Hazardous Substances Data: 213627-30-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
4-BROMOBENZYLMETHYLSULFONE is used as a reagent for [application reason] in the development of new drugs and therapeutic agents. Its versatile properties and potential therapeutic benefits contribute to ongoing research and exploration in medicinal chemistry.
Used in Organic Synthesis:
4-BROMOBENZYLMETHYLSULFONE is used as a reagent for [application reason] in organic synthesis, where it may be utilized as an intermediate in the production of other chemicals and pharmaceutical products.
Used in Medical Treatments:
4-BROMOBENZYLMETHYLSULFONE is used as a potential treatment for [application type] in the management of various medical conditions such as inflammation, pain, and oxidative stress-related disorders. Its potential applications in this area are currently under investigation.

Upstream product

• 15733-07-0 1-bromo-4-(methylsulfanylmethyl)benzene 
• 20277-69-4 sodium methansulfinate 
• 589-15-1 1-bromomethyl-4-bromobenzene 
• 873-75-6 4-bromobenzenemethanol 
• 2386-57-4 methanesulfonic acid sodium salt 
• 1122-91-4 4-bromo-benzaldehyde 

Downstream Products

• 638218-98-1 8-(4'-methanesulfonylmethyl-biphenyl-3-yl)-6-(1-methanesulfonyl-1-methyl-ethyl)-quinoline 
• 1446235-73-9 4-{2-[(4-fluorophenyl)amino]-5-[(methylsulfonyl)methyl]phenyl}-6-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one 

Relevant articles and documents

NOVEL APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS

The present invention relates to inhibitors of apoptosis signal-regulating kinase 1 ("ASK1"), a process for synthesis of the compounds of the present invention, composition comprising the compounds and use of the compounds for inhibition of ASK1.

Discovery and optimization of novel constrained pyrrolopyridone BET family inhibitors

Novel conformationally constrained BET bromodomain inhibitors have been developed. These inhibitors were optimized in two similar, yet distinct chemical series, the 6-methyl-1H-pyrrolo[2,3-c]pyridin-7(6H)-ones (A) and the 1-methyl-1H-pyrrolo[2,3-c]pyridin

CATHEPSIN K INHIBITOR AND APPLICATION THEREOF

The invention relates to capthepsin K inhibitors and uses thereof, specifically relates to a class of compounds having the formula (I) which are used for treating or preventing cathepsin dependent diseases or conditions, specifically, wherein the cathepsin is capthepsin K. The compounds and compositions thereof can be used as bone resorption inhibitors for the treatment of associated diseases.

BROMODOMAIN INHIBITORS

The present invention provides for compounds of formula (I) wherein R1, R2, R6, Y1, Y2, A1, A2, A3, and A4 have any of the values defined in the specificati

DIHYDRO-PYRROLOPYRIDINONE INHIBITORS

The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4, and R5 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).

TETRACYCLIC BROMODOMAIN INHIBITORS

The present invention provides for compounds of formula (I) wherein R1, R2, R6, Y1, Υ2, Υ3, A1, A2, A3 and A4 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).

4-AMINO-7,8-DIHYDROPYRIDO[4,3-d]PYRIMIDIN-5(6H)-ONE DERIVATIVES

The invention provides compounds of the general Formula (I) where R1, R2, and A are defined herein, as well as the preparation, compositions and uses thereof.

SMALL ORGANIC MOLECULE REGULATORS OF CELL PROLIFERATION

The present invention makes available methods and reagents for modulating proliferation or differentiation in a cell or tissue comprising contacting the cell with a compound. In certain embodiments, the methods and reagents may be employed to correct or inhibit an aberrant or unwanted growth state, e.g., by antagonizing a normal patched pathway or agonizing smoothened or hedgehog activity.

SMALL ORGANIC MOLECULE REGULATORS OF CELL PROLIFERATION

The present invention makes available methods and reagents for modulating proliferation or differentiation in a cell or tissue comprising contacting the cell with a compound. In certain embodiments, the methods and reagents may be employed to correct or inhibit an aberrant or unwanted growth state, e.g., by antagonizing a normal patched pathway or agonizing smoothened orhedgehog activity.

ACYL BIPIPERIDINYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT

Bipiperidyl compounds of the formula: (I) are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. Pharmaceutically acceptable salts and solvates are included as well. The compounds are useful as agonists of the g-protein coupled receptor GPR-119.